Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children

BACKGROUND: The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. We estimated the cost-effectiveness of introducing either PCV10 or the13-valent vaccine (PCV13) from a societal perspective and explored the incremental impact of including indirect vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayieko, Philip, Griffiths, Ulla K., Ndiritu, Moses, Moisi, Jennifer, Mugoya, Isaac K., Kamau, Tatu, English, Mike, Scott, J. Anthony G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691111/
https://www.ncbi.nlm.nih.gov/pubmed/23826268
http://dx.doi.org/10.1371/journal.pone.0067324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691111/
https://www.ncbi.nlm.nih.gov/pubmed/23826268
http://dx.doi.org/10.1371/journal.pone.0067324

Ejemplares similares